Mineralys Therapeutics (NASDAQ:MLYS) Posts Earnings Results, Misses Expectations By $0.30 EPS

Mineralys Therapeutics (NASDAQ:MLYS) announced its earnings results on Monday. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.30), Zacks reports. During the same quarter last year, the firm posted ($0.57) EPS.

Mineralys Therapeutics Price Performance

NASDAQ MLYS traded down $1.54 during trading on Tuesday, reaching $13.38. 397,621 shares of the company’s stock traded hands, compared to its average volume of 179,600. The firm has a market cap of $665.39 million, a price-to-earnings ratio of -5.51 and a beta of 1.71. The company’s 50 day simple moving average is $12.95 and its two-hundred day simple moving average is $12.64. Mineralys Therapeutics has a 12-month low of $5.85 and a 12-month high of $16.91.

Insider Buying and Selling at Mineralys Therapeutics

In other news, CFO Adam Scott Levy sold 10,757 shares of the company’s stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $13.57, for a total transaction of $145,972.49. Following the transaction, the chief financial officer now owns 236,854 shares in the company, valued at $3,214,108.78. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $13.57, for a total transaction of $145,972.49. Following the transaction, the chief financial officer now owns 236,854 shares in the company, valued at approximately $3,214,108.78. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jon Congleton sold 15,271 shares of the stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $13.52, for a total value of $206,463.92. Following the transaction, the chief executive officer now directly owns 895,941 shares of the company’s stock, valued at $12,113,122.32. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 51,510 shares of company stock valued at $735,431. 33.24% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a research note on Tuesday.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.